The present study was designed to determine the effects of a traditional Chinese medicine, called Qishen Yiqi Dropping Pill on chronic hypoxia-induced myocardial injury. To establish a rat chronic hypoxia model to be ...The present study was designed to determine the effects of a traditional Chinese medicine, called Qishen Yiqi Dropping Pill on chronic hypoxia-induced myocardial injury. To establish a rat chronic hypoxia model to be used in the evaluation of the therapeutic effects of the Qishen Yiqi Dropping Pill, Sprague-Dawley （SD） rats were randomly divided into three groups： the control, model, and treatment groups （n - 10 per group）. The animals were housed in a plexiglass container. The control animals were under normal oxygen concentration and the model and treatment groups were exposed to air and nitrogen for 5 weeks. The rats in the treatment group were orally administered the Qishen Yiqi Dropping pill （35 mg-kg-1.d-1） for 5 weeks. After the treatment, the cardiac function and morphology were analyzed, and the expression levels of hypoxia-inducible factor la （HIF-1a） were determined using Western blotting. Our results indicated that the cardiac function was impaired, cell apoptosis was enhanced, and HIF-1a expression was up-regulated in the model group, compared to the control group. These changes were ameliorated by the treatment with the Qishen Yiqi Dropping Pill. In conclusion, Qishen Yiqi Dropping pill can ameliorate myocardial injury induced by chronic hypoxia, improve cardiac function, and decrease myocardial cell apoptosis, which may provide a basis for its clinical use for the treatment of chronic cardiovascular diseases展开更多
目的对芪参益气滴丸治疗慢性心力衰竭的系统评价/Meta分析(SRs/MAs)进行再评价,以评估该领域研究质量和临床证据现状。方法计算机检索PubMed、EMbase、Cochrane Library、Web of Science、CNKI、WanFang Data和CBM数据库,搜集与研究目...目的对芪参益气滴丸治疗慢性心力衰竭的系统评价/Meta分析(SRs/MAs)进行再评价,以评估该领域研究质量和临床证据现状。方法计算机检索PubMed、EMbase、Cochrane Library、Web of Science、CNKI、WanFang Data和CBM数据库,搜集与研究目的相关的SRs/MAs,检索时限均为建库至2022年12月31日。由2名研究者独立筛选文献、提取资料,使用AMSTAR-2进行方法学质量评价,使用ROBIS评价偏倚风险,使用PRISMA进行报告质量评价,最后采用GRADE系统进行证据质量分级。结果最终纳入17个SRs/MAs。但纳入SRs/MAs的方法学质量、报告质量、偏倚风险评价结果及结局指标的证据等级均存在缺陷。根据AMSTAR-2评估结果,SRs/MAs的方法学质量以极低级为主;根据ROBIS评价结果,只有少数SRs/MAs被评估为低偏倚风险;PRISMA评价结果表明纳入的24项研究的报告质量较完整;根据GRADE证据分级结果,84个结局指标中证据质量为低级和极低级占比94%,局限性是导致其降级的主要因素,其次是发表偏倚、不一致性、不精确性及间接性。结论目前芪参益气滴丸治疗慢性心力衰竭具有较好的临床疗效,但是临床研究和二次研究设计和报告的规范性和科学性不足,导致临床推荐意见证据质量不高,还需要进一步规范和提高临床研究和二次研究质量。展开更多
文摘The present study was designed to determine the effects of a traditional Chinese medicine, called Qishen Yiqi Dropping Pill on chronic hypoxia-induced myocardial injury. To establish a rat chronic hypoxia model to be used in the evaluation of the therapeutic effects of the Qishen Yiqi Dropping Pill, Sprague-Dawley （SD） rats were randomly divided into three groups： the control, model, and treatment groups （n - 10 per group）. The animals were housed in a plexiglass container. The control animals were under normal oxygen concentration and the model and treatment groups were exposed to air and nitrogen for 5 weeks. The rats in the treatment group were orally administered the Qishen Yiqi Dropping pill （35 mg-kg-1.d-1） for 5 weeks. After the treatment, the cardiac function and morphology were analyzed, and the expression levels of hypoxia-inducible factor la （HIF-1a） were determined using Western blotting. Our results indicated that the cardiac function was impaired, cell apoptosis was enhanced, and HIF-1a expression was up-regulated in the model group, compared to the control group. These changes were ameliorated by the treatment with the Qishen Yiqi Dropping Pill. In conclusion, Qishen Yiqi Dropping pill can ameliorate myocardial injury induced by chronic hypoxia, improve cardiac function, and decrease myocardial cell apoptosis, which may provide a basis for its clinical use for the treatment of chronic cardiovascular diseases
文摘目的对芪参益气滴丸治疗慢性心力衰竭的系统评价/Meta分析(SRs/MAs)进行再评价,以评估该领域研究质量和临床证据现状。方法计算机检索PubMed、EMbase、Cochrane Library、Web of Science、CNKI、WanFang Data和CBM数据库,搜集与研究目的相关的SRs/MAs,检索时限均为建库至2022年12月31日。由2名研究者独立筛选文献、提取资料,使用AMSTAR-2进行方法学质量评价,使用ROBIS评价偏倚风险,使用PRISMA进行报告质量评价,最后采用GRADE系统进行证据质量分级。结果最终纳入17个SRs/MAs。但纳入SRs/MAs的方法学质量、报告质量、偏倚风险评价结果及结局指标的证据等级均存在缺陷。根据AMSTAR-2评估结果,SRs/MAs的方法学质量以极低级为主;根据ROBIS评价结果,只有少数SRs/MAs被评估为低偏倚风险;PRISMA评价结果表明纳入的24项研究的报告质量较完整;根据GRADE证据分级结果,84个结局指标中证据质量为低级和极低级占比94%,局限性是导致其降级的主要因素,其次是发表偏倚、不一致性、不精确性及间接性。结论目前芪参益气滴丸治疗慢性心力衰竭具有较好的临床疗效,但是临床研究和二次研究设计和报告的规范性和科学性不足,导致临床推荐意见证据质量不高,还需要进一步规范和提高临床研究和二次研究质量。
